Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775991 | 0.88 | THRB (0.39) | GRM5ADORA2AMLNRMTORLRRK2 | |
| SCHEMBL16775934 | 0.87 | USP30 (0.40) | GRM5ADORA2ALRRK2GSK3AGSK3B | |
| SCHEMBL16775985 | 0.87 | GRM5 (0.38) | GRM5ADORA2AMLNRMTORLRRK2 | |
| SCHEMBL19365517 | 0.86 | BRAF (0.40) | GRM5BRAFADORA2AMTORBRD4 | |
| SCHEMBL16775980 | 0.84 | GRM5 (0.39) | GRM5ADORA2AMLNRMTORLRRK2 | |
| SCHEMBL16775933 | 0.84 | USP30 (0.39) | GRM5ADORA2AMLNRMTORLRRK2 | |
| SCHEMBL19670392 | 0.84 | GRM5 (0.38) | GRM5BRAFADORA2AMLNRMTOR | |
| SCHEMBL16775982 | 0.83 | CACNA1G (0.43) | GRM5BRAF | |
| SCHEMBL16775983 | 0.83 | HDAC2 (0.39) | GRM5ADORA2AMLNRMTORGSK3B | |
| SCHEMBL16775990 | 0.83 | ADORA2A (0.39) | GRM5ADORA2AMLNRMTORLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885BRAF 3419/4885ADORA2A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.